Aurobindo Pharma Secures US FDA Approval for Tofacitinib Tablets

Final US FDA approval received for Tofacitinib Tablets (5 mg and 10 mg).
US market opportunity estimated at US$ 494 million.

Reader Takeaway: US FDA approval is positive; immediate launch targets significant market share.

What just happened

Aurobindo Pharma announced it has received the final approval from the U.S. Food and Drug Administration (US FDA) for its Tofacitinib Tablets in 5 mg and 10 mg dosages. These tablets are therapeutically equivalent to the reference drug Xeljanz Tablets. The company has stated that it plans to launch the product immediately.

Why this matters

This approval opens up a significant market opportunity for Aurobindo Pharma in the United States. The estimated market for Tofacitinib Tablets is US$ 494 million over the twelve months ending April 2026, according to IQVIA data. Gaining regulatory approval allows the company to tap into this revenue stream.

The backstory

The Tofacitinib Tablets are indicated for adult patients suffering from moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis. The drug's efficacy relies on its ability to manage these conditions when other treatments have been inadequate.

What changes now

Aurobindo Pharma can now commercially market and sell Tofacitinib Tablets in the US. The company's manufacturing facility, APL Healthcare Unit IV, will produce the drug. The immediate launch strategy suggests the company is poised to capture market share quickly.

Risks to watch

While the approval is a positive step, the company faces competition from other generic and branded manufacturers in the Tofacitinib market. Production efficiency at APL Healthcare Unit IV and effective market penetration will be crucial for success.

Peer comparison

Aurobindo Pharma has a strong track record of securing US FDA approvals. As of June 4, 2026, the company has achieved 586 total USFDA ANDA approvals, with 561 being final approvals.

Context metrics (time-bound)

The estimated US market size for Tofacitinib Tablets (5 mg and 10 mg) is US$ 494 million for the twelve months ending April 2026.

What to track next

Investors will be keen to see the sales performance of Tofacitinib Tablets in the coming quarters and how it contributes to Aurobindo Pharma's overall revenue and profitability in the US market. Monitoring further pipeline approvals will also be key.